On April 17, 2023 Lassen Therapeutics, a clinical-stage biotech company developing breakthrough antibody therapeutics as potential treatments for immuno-fibrotic diseases and cancer, reported that it will present new preclinical data demonstrating activity of its anti-interleukin-18 binding protein (IL-18BP) antibody and efficacy in combination with anti-PD-1 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, being held in Orlando, Florida (Press release, Lassen Therapeutics, APR 17, 2023, View Source [SID1234630215]). The poster presentation is part of the Immunomodulatory Agents and Interventions session which takes place today, Monday April 17th, from 9:00 AM to 12:30 PM ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IL-18BP is a soluble inhibitory decoy receptor that binds to interleukin-18 (IL-18) and serves as a checkpoint to modulate and inhibit the potent proinflammatory effects of IL-18 on both the innate and adaptive immune system. IL-18 has demonstrated efficacy in certain tumor models; IL-18 clinical trials have not, however, shown efficacy of this treatment due to increased expression of IL-18BP with consequent inhibition of activity.
Lassen’s anti-IL18BP antibodies demonstrated anti-tumor efficacy in a mouse syngeneic tumor model in combination with IL-18, anti-PD-1, and anti-PD-1 plus IL-18. The antibodies have been shown to induce potent stimulation of interferon gamma and other proinflammatory cytokines and chemokines in vitro and in vivo.
"We have identified high affinity, high potency anti-IL-18BP antibodies capable of disrupting and inhibiting the formation of IL-18BP/IL-18 complexes to liberate IL-18," said David King, PhD, Chief Scientific Officer of Lassen. "Our data suggest that inhibition of IL-18BP/IL-18 binding may prove efficacious in the treatment of cancers by increasing the immunostimulatory effects of IL-18 in tumors.